Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19
ReviewHumansWith sodium cromoglycate (proposed partner)
This study tested palmitoylethanolamide together with sodium cromoglycate (proposed partner). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Could sodium cromoglycate and palmitoylethanolamide calm mast cell-driven lung inflammation in COVID-19? A hypothesis paper on mast cell activation in SARS-CoV-2 lung inflammation and on both compounds as mast cell modulators.
What the authors reported
Sodium cromoglycate and/or PEA are proposed to suppress mast cell activation and release of pro-inflammatory mediators in the lungs of COVID-19 patients. This is a hypothesis; no patients were studied and no data are reported.
Limits of this study
A hypothesis paper with no experimental or clinical data. It cannot show that either compound works in COVID-19. The authors declare no competing interests.
Source
PubMed 32460208 · doi:10.1016/j.mehy.2020.109856
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.